Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06571734

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

A Single-Arm, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic Leiomyosarcoma Unresectable Leiomyosarcoma

Interventions Biospecimen Collection Computed Tomography Echocardiography Multigated Acquisition Scan Zanzalintinib

Updated 4 times since 2024 Last updated: Jan 7, 2026 Started: Sep 19, 2024 Primary completion: Jul 1, 2028 Completion: Jul 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Leiomyosarcoma and Unresectable Leiomyosarcoma and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Aug 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Nov 2024 — Aug 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States